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Background: Marine-Lenhart syndrome is defined as the co-occurrence of Graves’ disease and functional nodules.
The vast majority of autonomous adenomas are benign, whereas functional thyroid carcinomas are considered to
be rare. Here, we describe a case of simultaneous occurrence of Marine-Lenhart syndrome and a papillary
microcarcinoma embedded in a functional nodule.
Case presentation: A 55 year-old, caucasian man presented with overt hyperthyroidism (thyrotropin (TSH) <0.01 μIU/L;
free thyroxine (FT4) 3.03 ng/dL), negative thyroid peroxidase and thyroglobulin autoantibodies, but elevated thyroid
stimulating hormone receptor antibodies (TSH-RAb 2.6 IU/L). Ultrasound showed a highly vascularized hypoechoic
nodule (1.1 × 0.9 × 2 cm) in the right lobe, which projected onto a hot area detected in the 99mtechnetium thyroid
nuclear scan. Overall uptake was increased (4.29%), while the left lobe showed lower tracer uptake with no visible
background-activity, supporting the notion that both Graves’ disease and a toxic adenoma were present. After normal
thyroid function was reinstalled with methimazole, the patient underwent thyroidectomy. Histological work up revealed
a unifocal papillary microcarcinoma (9 mm, pT1a, R0), positively tested for the BRAF V600E mutation, embedded into the
hyperfunctional nodular goiter.
Conclusions: Neither the finding of an autonomously functioning thyroid nodule nor the presence of Graves’ disease
rule out papillary thyroid carcinoma.
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The eponym Marine-Lenhart syndrome is typically used
for the rare condition of concurrent manifestation of
Graves’ disease and thyroid autonomy (Plummer’s dis-
ease) [1-3]. In general, the majority of autonomic aden-
omas of the thyroid are benign, whereas autonomic
thyroid carcinomas are considered a relatively rare find-
ing [4,5]. Here, we report the exceptional case of simul-
taneous occurrence of Marine-Lenhart syndrome and a
papillary microcarcinoma, which was embedded in an
autonomous adenoma.* Correspondence: alois.gessl@meduniwien.ac.at
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reproduction in any medium, provided the orCase presentation
A 55-year-old Caucasian man was referred because of
abnormal thyroid function tests and intermittent atrial
fibrillation. He reported of occasional palpitations, epi-
sodes of tachycardia (up to 200 bpm), especially under
exertion, and excessive sweating. The patient was previ-
ously started on bisoprolol 2.5 mg once daily and
presented with normofrequent sinus rhythm. On phys-
ical examination his thyroid was moderately enlarged
(WHO grade Ib) and soft. Thyroid function tests re-
vealed hyperthyroidism with complete suppression of
thyroid stimulating hormone (TSH) (<0.01 μIU/mL, see
Table 1 for reference range), elevated FT4 (3.03 ng/dL)
and increased total thyroxine (TT4) and total triiodo-
thyronine (TT3) levels (132 and 2.53 ng/mL respect-
ively). Thyroid peroxidase (TPO) and thyroglobulinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.









FT4 (0.76 – 1.66 ng/dL) 3.03 2.09 1.44 1.27
TSH (0.44 – 3.77 μIU/mL) <0.01 <0.01 <0.01 7.26
TT4 (58 – 124 ng/mL) 132 109 90 80
TT3 (0.8 – 1.8 ng/mL) 2.53 1.91 1.49 0.89
TgAb (< 33 IU/mL) <10 ND ND <10
TPO (< 28 IU/mL) 9 ND ND ND
TSH-RAb (< 1.75 IU/L) 2.6 ND ND ND
TBG (14 – 32 μg/mL) 19.7 19 ND 28.7
Tg (1.6 – 55 ng/mL) ND ND ND 5.7
Calcitonin (< 8 pg/mL) 2.7 ND ND ND
ND – not determined.
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were elevated (2.6 IU/L), indicating that the patient suf-
fered from Graves’ disease (See Table 1). Upon initial ad-
mission the patient showed no clinical signs of Graves’
orbitopathy. A thyroid ultrasound showed multiple
hypoechoic nodules in both thyroid lobes. The most
prominent nodule appeared in anterior caudal position of
the right lobe embedded in a diffusely heterogeneous thy-
roid gland. The lesion measured 1.1 × 0.9 × 2 cm, showed
no signs of microcalcification, but was highly vascularized
in the Doppler color flow, whereas the rest of the thyroid
tissue showed moderate signs of hypervascularization
(Figure 1). A 99mTechnetium thyroid nuclear scan
displayed an orthotopic, V-shaped thyroid with asymmet-
rical uptake and a hot area in the right lower lobe compat-
ible with the hypoechoic, hypervascularized lesion
discovered in ultrasonography (Figure 2). Uptake in the
remaining thyroid tissue was comparatively lower but not
suppressed, with increased overall uptake (4.29%, refer-
ence range: 0.5% – 2%) and almost no detectable back-
ground activity. Thus, both signs of Graves’ disease and
thyroid autonomy were coexisting in our patient hence
the diagnosis Marine-Lenhart syndrome.
The patient was then started on 20 mg methimazole
twice daily for the first seven days after his initial pres-
entation, followed by 20 mg methimazole once daily for
the following 8 weeks, which completely resolved his
hyperthyroid condition until follow up 2 (Table 1). How-
ever, because of the unlikeliness of a permanent remis-
sion, the existence of multiple “cold” nodules and the
relative resistance of patients with coexisting Graves’ dis-
ease and toxic adenoma to radioiodine therapy [2], a de-
finitive, surgical treatment was aspired. The patient
therefore underwent thyroidectomy three months after
initial diagnosis. The patient received alternating 10 mg
and 20 mg methimazole once daily until the thyroid
gland was removed. After thyroid surgery bisoprolol 2.5mg once daily was stopped. Notably, embedded in the
nodular area of the right thyroid lobe a, macroscopically,
white and firm elastic area was discovered, which was diag-
nosed as a papillary microcarcinoma (5 mm) in an
intraoperative frozen section. Histological work-up re-
vealed a unifocal papillary microcarcinoma (9 mm, pT1a,
R0) in the right thyroid lobe with signs of a hyperfunc-
tioning nodular goiter (see Figure 3 A and B). Furthermore,
the carcinoma sections were positively tested for the BRAF
V600E mutation using the ViennaLab BRAF Strip Assay
(Vienna, Austria) (Figure 3C). After a short postope-
rative recovery phase the patient was discharged under
levothyroxine therapy.
A postoperative follow up 17 weeks after the initial
diagnosis showed subclinical hypothyroidism, which was
fixed by adjusting the levothyroxine therapy (Table 1).
Notably, the patient developed a moderately active
orbitopathy postoperatively, which was treated with IV
corticosteroids for 3 months.
Discussion
The BRAF V600E mutation is usually associated with
higher malignancy and aggressiveness in papillary thyroid
carcinomas [6] and in most cases with typical ultrasound
features of thyroid malignancy [7]. However, due to the
unifocality of the lesion and the fact that the papillary car-
cinoma in our patient measured less than 10 mm,
according to the 2009 consensus of the American Thyroid
Association no radioiodine therapy was performed [8].
Therefore, postsurgical thyroglobulin (TG) levels are still
detectable in our patient (Table 1) and only of limited use
in postsurgical follow up.
It is commonly believed that papillary microcarcinomas
only rarely collocate within toxic thyroid adenomas, al-
though several case reports are found in the literature
[9-16]. A selection of retrospective studies estimate the
risk of concurrent papillary carcinomas in functioning
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Figure 1 Ultrasound. Thyroid ultrasound transverse (A, B and C) and sagittal view (D and E) of the right and left thyroid lobe showing a
diffusely heterogenous gland with a clearly demarcated hypoechoic hypervascularized nodule in an anterior caudal position of the right lobe.
Scherer et al. BMC Endocrine Disorders 2013, 13:16 Page 3 of 6
http://www.biomedcentral.com/1472-6823/13/16nodules ranging from 0.34% up to 5% [5,17,18]. In a
cohort of US children with toxic adenoma the malignancy
rate was yet higher (about 11%) [19]. Thus, despite the
relatively low risk of malignant transformation of func-
tioning nodules, these lesions need careful clinical follow
up with ultrasound and possibly fine needle aspiration bi-
opsy especially when patients are young.
Furthermore, it is still subject of debate whether the fre-
quency of thyroid cancer is higher in patients with Graves’
disease, mostly because the studies are typically retrospect-
ive and extend over a long period of time, where diagnostic
capabilities and tools might have changed significantly (ex-
tensively reviewed in [20]). However, it seems that the
prevalence of palpable nodules is about 3-fold higher inGraves’ patients (15.8%) [21] compared to the general
population living in a non-endemic region (5%) [22]. Stud-
ies relying on ultrasound imaging also find a higher preva-
lence for thyroid nodules in patients suffering form Graves’
disease (33.6%) [23] compared to the general population
(about 26%) although to a lesser extent [24,25]. Of note, in
the former study more than half the patients suffering from
Graves’ disease developed thyroid nodules during the 2-
year follow up, which suggests that Graves’ disease pro-
motes de novo thyroid nodule formation [23]. Furthermore,
the mean malignancy rate of palpable nodules in Graves’
patients is about 16% versus a 5% malignancy rate in the
general population (reviewed in [26]). Thus, in conjunction
with the above-mentioned prevalence rates of thyroid
Activity: 80 MBq 99mTc
20min post inject.
Uptake: 4.28%
Figure 2 Thyroid Scan. Thyroid nuclear scan, showed an orthotopic, V-shaped thyroid gland with accentuated radiotracer uptake into the right
lobe. The uptake within the right lobe was heterogeneous with a focal area of relatively increased tracer accumulation centro-caudally, which
projected onto the location of the hypervascularized adenoma, detected in the ultrasound. Background-activitiy was completely missing, which is
compatible with Graves’ disease. A small pyramidal lobe is emanating from the right lobe.
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almost 10-fold higher chance of developing thyroid cancer.
In a retrospective multicenter study with more than 500
Graves’ patients thyroid carcinomas were found in 3.8% (20
out of 21 were papillary carcinomas) [27]. Another study
matched these results and found a malignancy rate of 3.3%A
B
Figure 3 Histology. (A, B) H&E histology of papillary thyroid carcinoma, A
high power. (C) Strip Assay demonstrating BRAF V600E mutation: Strip #1 p
fixed paraffin embedded sections of carcinoma tissue were evaluated for thin their collective of Graves’ patients [28], whereas the inci-
dence of thyroid cancer in the general US population was
estimated at about 14.4 per 100,000 [29]. Of note, in the
former study all papillary carcinomas were detected within
thyroid nodules embedded into a Graves’ goiter. In total
15% of the patients suffering from both, nodules andC
, characteristic morphology at low power, B Nuclear morphology at
atient, strip #2 negative control, strip #3 positive control; Formalin
e BRAF V600E mutation by using the ViennaLab BRAF Strip Assay.
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other study the risk for malignancy of a thyroid nodule
within a toxic diffuse goiter even reached 22% [30], there-
fore any nodule within a Graves’ goiter should be carefully
examined to rule out a thyroid carcinoma.
There is evidence that thyroid cancer in Graves’ pa-
tients is more aggressive. Therefore, an important ques-
tion is, whether the presence of Graves’ disease in
thyroid cancer patients affects their clinical outcome.
Studies have found that in Graves’ patients thyroid car-
cinomas grow more invasively and develop lymph node
and distant metastases more frequently compared to eu-
thyroid controls [31-33], although a more recent study
was not able to confirm these data [34]. Yet, given the
possibility that Graves’ disease increases nodule for-
mation and their respective risk for malignant tran-
sformation, it is conceivable that Graves’ disease may
constitute an additional risk factor when managing thy-
roid cancer patients lowering the threshold for surgical
intervention.
Color flow Doppler sonography has proven a useful tool
in the differential diagnosis of toxic multinodular goiter.
Boi et al. have indicated that hyperthyroid patients with
multinodular goiter can be subdivided into two distinct
groups using color flow Doppler patterns: 1) Nodules with
normal vascularization surrounded by hypervascularized
hypoechoic thyroid tissue showing a similar picture as in
Graves’ patients. Notably, in 44% of these patients TSH re-
ceptor antibodies were elevated; and 2) heterogenous
hypervascularized nodules embedded into normoechoic-
normovascular thyroid parenchyma. None of these patients
were tested positive for TSH receptor antibodies [35]. The
first group constitutes a group of patients, who probably
developed Graves’ disease in a non-toxic multinodular goi-
ter. Our patient on the other hand showed features of both
groups. His prominent nodule was heterogeneous and
clearly more vascularized compared to the surrounding
thyroid parenchyma matching the ultrasound criteria of
group 2). However, his TSH receptor antibody titers were
also elevated, indicating that both thyroid autonomy and
Graves’ disease are concurrent.
Finally, hyperthyroid patients have a disproportionate in-
crease in T3 compared to T4 levels [36]. Laurberg et al.
have found that this probably results from a relative in-
crease in type 1 iodothyronine deiodinase activity in hyper-
thyroid patients compared to healthy subjects, where type
2 iodothyronine deiodinase accounts for the majority of T3
production [37,38]. Our patient with Marine-Lenhart syn-
drome also presented with an increased T3 to T4 ratio of
1.9%. This matches what Laurberg et al. have found in their
collective of multinodular toxic goiter. Their patients with
thyroid autonomy had a lower T3/T4 ratio compared to
those with Graves’ disease (2.0 versus 2.7%) [38], suggesting
that in our patient the autonomous adenoma was the moreprominent component of disease, which is also supported
by the relatively low levels of circulating TSH-RAb and thy-
roid uptake in the region outside of the adenoma.
Conclusion
Taken together, neither the finding of an autonomously
functioning thyroid nodule nor the presence of Graves’
disease can rule out a papillary thyroid carcinoma. Al-
though, there is still some debate whether Graves’ disease
increases the risk for thyroid cancer, nodules embedded in
a Graves’ goiter should be carefully evaluated for malig-
nant transformation especially when patients are young.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Series Editor of this journal.
Abbreviations
FT4: Free thyroxine; TSH: Thyrotropin or thyroid-stimulating hormone;
TT4: Total thyroxine; TT3: Total triiodothyronine; TgAb: Thyroglobulin
antibody; TPO: Thyroperoxidase antibody; TSH-RAb: Thyroid stimulating
hormone receptor antibody; TBG: Thyroxine-binding globulin;
Tg: Thyroglobulin; ND: Not determined.
Competing interest
The authors declare that no financial conflict of interest exists.
Authors’ contributions
T.S. compiled data and wrote the manuscript, E.W.K. and M.B.E. researched
data and contributed to discussion, C.P. performed thyroid surgery, A.R.C.
performed the histologic and molecular analyses, M.K. edited the manuscript
and contributed to discussion, A.G. identified the case and wrote the
manuscript. All authors read and approved the final manuscript.
Author details
1Division of Endocrinology and Metabolism, Department of Internal Medicine III,
Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
2Department of Surgery, SMZ Floridsdorf, Hinaysgasse 1, Vienna 1210, Austria.
3Institute of Pathology, Danube Hospital, Langobardenstr. 122, Vienna 1220,
Austria.
Received: 9 November 2012 Accepted: 23 April 2013
Published: 8 May 2013
References
1. Biersack HJ, Biermann K: The Marine-Lenhart syndrome revisited. Wien Klin
Wochenschr 2011, 123:459–462.
2. Charkes ND: Graves’ disease with functioning nodules (Marine-Lenhart
syndrome). J Nucl Med 1972, 13:885–892.
3. Marine D, Lenhart CH: Pathological anatomy of exophthalmic goiter: the
anatomical and physiological relations of the thyroid gland to the
disease; the treatment. Arch Intern Med 1911, VIII:265–316.
4. Harach HR, Sanchez SS, Williams ED: Pathology of the autonomously
functioning (hot) thyroid nodule. Ann Diagn Pathol 2002, 6:10–19.
5. Erdogan MF, Anil C, Ozer D, Kamel N, Erdogan G: Is it useful to routinely
biopsy hot nodules in iodine deficient areas? J Endocrinol Invest 2003,
26:128–131.
6. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella
V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R: BRAF(V600E)
mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer
2008, 15:191–205.
7. Kabaker AS, Tublin ME, Nikiforov YE, Armstrong MJ, Hodak SP, Stang MT,
McCoy KL, Carty SE, Yip L: Suspicious Ultrasound Characteristics Predict
Scherer et al. BMC Endocrine Disorders 2013, 13:16 Page 6 of 6
http://www.biomedcentral.com/1472-6823/13/16BRAF V600E-Positive Papillary Thyroid Carcinoma. Thyroid 2012, 22
(6):585–589. doi:10.1089/thy.2011.0274. Epub 2012 Apr 23.
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri
EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM:
Revised american thyroid association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer. Thyroid
2009, 19:1167–1214.
9. De Rosa G, Testa A, Maurizi M, Satta MA, Aimoni C, Artuso A, Silvestri E,
Rufini V, Troncone L: Thyroid carcinoma mimicking a toxic adenoma. Eur J
Nucl Med 1990, 17:179–184.
10. Kim TS, Asato R, Akamizu T, Harada D, Nakashima Y, Higashi T, Yamamoto N,
Tamura Y, Tamaki H, Hirano S, Tanaka S, Ito J: A rare case of hyperfunctioning
papillary carcinoma of the thyroid gland. Acta Otolaryngol Suppl 2007, 557:55–57.
11. Lamberg BA, Makinen J, Murtomaa M: Papillary thyroid carcinoma in a
toxic adenoma. Nuklearmedizin 1976, 15:138–141.
12. Laroche C, Cremer GA, Sereni D, Dero M: Papillary thyroid cancer lying
within a toxic adenoma (author’s transl). Ann Med Interne (Paris) 1979,
130:675–678.
13. Majima T, Doi K, Komatsu Y, Itoh H, Fukao A, Shigemoto M, Takagi C,
Corners J, Mizuta N, Kato R, Nakao K: Papillary thyroid carcinoma without
metastases manifesting as an autonomously functioning thyroid nodule.
Endocr J 2005, 52:309–316.
14. Nishida AT, Hirano S, Asato R, Tanaka S, Kitani Y, Honda N, Fujiki N, Miyata K,
Fukushima H, Ito J: Multifocal hyperfunctioning thyroid carcinoma
without metastases. Auris Nasus Larynx 2008, 35:432–436.
15. Tfayli HM, Teot LA, Indyk JA, Witchel SF: Papillary thyroid carcinoma in an
autonomous hyperfunctioning thyroid nodule: case report and review of
the literature. Thyroid 2010, 20:1029–1032.
16. Uludag M, Yetkin G, Citgez B, Isgor A, Basak T: Autonomously functioning
thyroid nodule treated with radioactive iodine and later diagnosed as
papillary thyroid cancer. Hormones (Athens) 2008, 7:175–179.
17. Rosler H, Wimpfheimer C, Ruchti C, Kinser J, Teuscher J: Hyperthyroidism in
thyroid cancer. Retrospective study of 53 cases. Nuklearmedizin 1984,
23:293–300.
18. Mizukami Y, Michigishi T, Nonomura A, Yokoyama K, Noguchi M, Hashimoto
T, Nakamura S, Ishizaki T: Autonomously functioning (hot) nodule of the
thyroid gland. A clinical and histopathologic study of 17 cases. Am J Clin
Pathol 1994, 101:29–35.
19. Croom RD 3rd, Thomas CG Jr, Reddick RL, Tawil MT: Autonomously
functioning thyroid nodules in childhood and adolescence. Surgery 1987,
102:1101–1108.
20. Pazaitou-Panayiotou K, Michalakis K, Paschke R: Thyroid cancer in patients
with hyperthyroidism. Horm Metab Res 2012, 44:255–262.
21. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker
DV: Malignant and benign neoplasms of the thyroid in patients treated
for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy
follow-up study. J Clin Endocrinol Metab 1974, 38:976–998.
22. Vander JB, Gaston EA, Dawber TR: The significance of nontoxic thyroid
nodules. Final report of a 15-year study of the incidence of thyroid
malignancy. Ann Intern Med 1968, 69:537–540.
23. Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D:
Thyroid nodules in Graves disease and the risk of thyroid carcinoma.
Arch Intern Med 1999, 159:1705–1708.
24. Brander A, Viikinkoski P, Nickels J, Kivisaari L: Thyroid gland: US screening
in a random adult population. Radiology 1991, 181:683–687.
25. Chung WY, Chang HS, Kim EK, Park CS: Ultrasonographic mass screening
for thyroid carcinoma: a study in women scheduled to undergo a breast
examination. Surg Today 2001, 31:763–767.
26. Belfiore A, Russo D, Vigneri R, Filetti S: Graves’ disease, thyroid nodules
and thyroid cancer. Clin Endocrinol (Oxf ) 2001, 55:711–718.
27. Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset
J, Marechaud R, Barbier J: Multicentre study of thyroid nodules in patients
with Graves’ disease. Br J Surg 2000, 87:1111–1113.
28. Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hong SJ, Shong
YK: Ultrasonographic screening for detection of thyroid cancer in
patients with Graves’ disease. Clin Endocrinol (Oxf ) 2004, 60:719–725.
29. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277–300.
30. Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P,
Arganini M, Pinchera A: Thyroid carcinoma in thyrotoxic patients treated
by surgery. J Endocrinol Invest 1988, 11:107–112.31. Ozaki O, Ito K, Kobayashi K, Toshima K, Iwasaki H, Yashiro T: Thyroid
carcinoma in Graves’ disease. World J Surg 1990, 14:437–440. discussion
440–431.
32. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R: Outcome of
differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metab
1998, 83:2805–2809.
33. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito
O, Vigneri R: Increased aggressiveness of thyroid cancer in patients with
Graves’ disease. J Clin Endocrinol Metab 1990, 70:830–835.
34. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K: Recent
outcome of Graves’ disease patients with papillary thyroid cancer. Eur J
Endocrinol 2007, 157:325–329.
35. Boi F, Loy M, Piga M, Serra A, Atzeni F, Mariotti S: The usefulness of
conventional and echo colour Doppler sonography in the differential
diagnosis of toxic multinodular goitres. Eur J Endocrinol 2000, 143:339–346.
36. Nicoloff JT, Low JC, Dussault JH, Fisher DA: Simultaneous measurement of
thyroxine and triiodothyronine peripheral turnover kinetics in man. J Clin
Invest 1972, 51:473–483.
37. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR: Type 2 iodothyronine
deiodinase is the major source of plasma T3 in euthyroid humans. J Clin
Invest 2005, 115:2524–2533.
38. Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K,
Pedersen KM: Sources of circulating 3,5,3′-triiodothyronine in
hyperthyroidism estimated after blocking of type 1 and type 2
iodothyronine deiodinases. J Clin Endocrinol Metab 2007, 92:2149–2156.
doi:10.1186/1472-6823-13-16
Cite this article as: Scherer et al.: A Case of simultaneous occurrence of
Marine – Lenhart syndrome and a papillary thyroid microcarcinoma.
BMC Endocrine Disorders 2013 13:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
